Suppr超能文献

作为具有多种结合模式的p53-Y220C裂隙结合剂的SAr反应性吡嗪衍生物

SAr Reactive Pyrazine Derivatives as p53-Y220C Cleft Binders with Diverse Binding Modes.

作者信息

Klett Theresa, Stahlecker Jason, Schwer Martin, Jaag Simon J, Masberg Benedikt, Knappe Cornelius, Lämmerhofer Michael, Stehle Thilo, Boeckler Frank M

机构信息

Laboratory for Molecular Design & Pharmaceutical Biophysics, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, 72076, Germany.

Pharmaceutical (Bio-) Analysis, Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, 72076, Germany.

出版信息

Drug Des Devel Ther. 2025 Jun 3;19:4727-4753. doi: 10.2147/DDDT.S513792. eCollection 2025.

Abstract

PURPOSE

The tumor suppressor p53 is most commonly mutated in human cancer. The structural mutant in the β-sandwich of the protein, p53-Y220C, is the ninth most common p53 mutant. The p53-Y220C mutant has a solvent-accessible hydrophobic pocket, leading to thermal destabilization of the protein. Screening of our covalent fragment library (CovLib) revealed the highly reactive pyrazine derivatives SN006 and SN007, which arylate among other cysteines in p53, the mutation-generated Cys220. Herein, comprehensive structure-activity relationship (SAR) studies of these intrinsically reactive CovLib hits were performed, aiming to identify improved stabilizers for p53-Y220C, with a more balanced reactivity profile, diverse binding modes and a better potential for chemical optimization.

METHODS

The compounds were screened for enhanced stabilization of p53 wild type and its mutants using differential scanning fluorimetry (DSF). To confirm covalent modification, intact mass spectrometry was performed. Thiol reactivity profiles were determined using a standardized Glutathione-modifying (GSH) assay. The binding modes of the identified hits and covalent modification of Cys220 were elucidated by X-ray crystallography. Moreover, the influence of the hits on the DNA-binding affinity of full-length p53 was investigated employing a fluorescence polarization assay (FPA).

RESULTS AND CONCLUSION

The promising pyrazine derivatives SN006/7-3, SN006/7-8, and SN006/7-9 were identified, occupying different subsites of the Y220C binding pocket. The compound SN006/7-8 substantially stabilized the thermosensitive cancer mutant Y220C by up to 5.0 °C, representing a strong enhancement over SN006 (1.8 °C) and SN007 (2.0 °C).

摘要

目的

肿瘤抑制因子p53在人类癌症中最常发生突变。该蛋白β折叠结构中的结构性突变体p53-Y220C是第九种最常见的p53突变体。p53-Y220C突变体有一个溶剂可及的疏水口袋,导致蛋白质热稳定性降低。对我们的共价片段文库(CovLib)进行筛选后发现了高反应活性的吡嗪衍生物SN006和SN007,它们能与p53中的其他半胱氨酸发生芳基化反应,包括由突变产生的Cys220。在此,对这些具有内在反应活性的CovLib命中化合物进行了全面的构效关系(SAR)研究,旨在识别出能更好地稳定p53-Y220C的化合物,使其具有更平衡的反应活性、多样的结合模式以及更好的化学优化潜力。

方法

使用差示扫描荧光法(DSF)筛选化合物对p53野生型及其突变体的增强稳定性。为确认共价修饰,进行了完整质谱分析。使用标准化的谷胱甘肽修饰(GSH)测定法确定硫醇反应活性谱。通过X射线晶体学阐明所鉴定命中化合物的结合模式以及Cys220的共价修饰情况。此外,采用荧光偏振测定法(FPA)研究命中化合物对全长p53 DNA结合亲和力的影响。

结果与结论

鉴定出了有前景的吡嗪衍生物SN006/7-3、SN006/7-8和SN006/7-9,它们占据Y220C结合口袋的不同亚位点。化合物SN006/7-8可将热敏性癌症突变体Y220C的稳定性大幅提高多达5.0℃,相较于SN006(1.8℃)和SN007(2.0℃)有显著增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8855/12212008/b2c463b9975c/DDDT-19-4727-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验